This illustration, which shows recognition of siRNA conjugated to trivalent N-acetylgalactosamine by the asialoglycoprotein receptor (ASGPR) expressed on the surface of a hepatocyte, and intracellular events that result in gene silencing, was featured as a cover image for ChemBioChem in April 2015.

In 2016, Alnylam Pharmaceuticals was on the verge of commercialization. Clinical application of RNA interference (RNAi) could potentially become FDA-approved for the treatment of certain rare diseases. Alnylam chose the 10th anniversary of RNAi winning the Nobel Prize to celebrate this advancement in medical technology and share its R&D story for the first time.